SACUBITRIL / VALSARTAN

The first of the class of dual neprilysin and angiotensin receptor inhibitors (ARNI).
Sacubitril/Valsartan Therapy in HF With Reduced Ejection Fraction (HFrEF) Patients After an Acute Decompensation Event] trials demonstrated that early administration of sacubitril/valsartan during hospitalization improves prognostic markers and reduces the risk of rehospitalization relative to enalapril